Pralatrexate Solution for Intravenous Injection Articles

Spectrum extends tender offer for Allos

9 July 2012

Spectrum plunges on negative trial results; makes bid for Allos

10 April 2012

Allos Thera questions CHMP Folotyn decision; posts new data

31 January 2012

Allos Therapeutics and Mundipharma ink $360 million deal for Folotyn

13 May 2011

Spectrum Pharma licenses lymphoma drug belinostat from TopoTarget for up to $350 million

3 February 2010

Celgene buys rival Gloucester for $640 million, gaining rights to Istodax; Allos defends price of Folotyn

8 December 2009

US FDA approves J&J’s psoriasis drug Stelara and Allos’ cancer agent Folotyn

28 September 2009

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end